Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017

Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE) against dominant influenza A(H3N2) viruses considered antigenically matched to the clade 3C.2a vaccine strain. Sequence analysis revealed substan...

Descripción completa

Detalles Bibliográficos
Autores principales: Skowronski, Danuta M, Chambers, Catharine, Sabaiduc, Suzana, Dickinson, James A, Winter, Anne-Luise, De Serres, Gaston, Drews, Steven J, Jassem, Agatha, Gubbay, Jonathan B, Charest, Hugues, Balshaw, Robert, Bastien, Nathalie, Li, Yan, Krajden, Mel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2017
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316907/
https://www.ncbi.nlm.nih.gov/pubmed/28205503
http://dx.doi.org/10.2807/1560-7917.ES.2017.22.6.30460
_version_ 1782508915436552192
author Skowronski, Danuta M
Chambers, Catharine
Sabaiduc, Suzana
Dickinson, James A
Winter, Anne-Luise
De Serres, Gaston
Drews, Steven J
Jassem, Agatha
Gubbay, Jonathan B
Charest, Hugues
Balshaw, Robert
Bastien, Nathalie
Li, Yan
Krajden, Mel
author_facet Skowronski, Danuta M
Chambers, Catharine
Sabaiduc, Suzana
Dickinson, James A
Winter, Anne-Luise
De Serres, Gaston
Drews, Steven J
Jassem, Agatha
Gubbay, Jonathan B
Charest, Hugues
Balshaw, Robert
Bastien, Nathalie
Li, Yan
Krajden, Mel
author_sort Skowronski, Danuta M
collection PubMed
description Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE) against dominant influenza A(H3N2) viruses considered antigenically matched to the clade 3C.2a vaccine strain. Sequence analysis revealed substantial heterogeneity in emerging 3C.2a1 variants by province and over time. Adjusted VE was 42% (95% confidence interval: 18–59%) overall, with variation by province. Interim virological and VE findings reported here warrant further investigation to inform potential vaccine reformulation.
format Online
Article
Text
id pubmed-5316907
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-53169072017-02-28 Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017 Skowronski, Danuta M Chambers, Catharine Sabaiduc, Suzana Dickinson, James A Winter, Anne-Luise De Serres, Gaston Drews, Steven J Jassem, Agatha Gubbay, Jonathan B Charest, Hugues Balshaw, Robert Bastien, Nathalie Li, Yan Krajden, Mel Euro Surveill Rapid Communication Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE) against dominant influenza A(H3N2) viruses considered antigenically matched to the clade 3C.2a vaccine strain. Sequence analysis revealed substantial heterogeneity in emerging 3C.2a1 variants by province and over time. Adjusted VE was 42% (95% confidence interval: 18–59%) overall, with variation by province. Interim virological and VE findings reported here warrant further investigation to inform potential vaccine reformulation. European Centre for Disease Prevention and Control (ECDC) 2017-02-09 /pmc/articles/PMC5316907/ /pubmed/28205503 http://dx.doi.org/10.2807/1560-7917.ES.2017.22.6.30460 Text en This article is copyright of The Authors, 2017. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Skowronski, Danuta M
Chambers, Catharine
Sabaiduc, Suzana
Dickinson, James A
Winter, Anne-Luise
De Serres, Gaston
Drews, Steven J
Jassem, Agatha
Gubbay, Jonathan B
Charest, Hugues
Balshaw, Robert
Bastien, Nathalie
Li, Yan
Krajden, Mel
Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017
title Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017
title_full Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017
title_fullStr Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017
title_full_unstemmed Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017
title_short Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017
title_sort interim estimates of 2016/17 vaccine effectiveness against influenza a(h3n2), canada, january 2017
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316907/
https://www.ncbi.nlm.nih.gov/pubmed/28205503
http://dx.doi.org/10.2807/1560-7917.ES.2017.22.6.30460
work_keys_str_mv AT skowronskidanutam interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017
AT chamberscatharine interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017
AT sabaiducsuzana interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017
AT dickinsonjamesa interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017
AT winteranneluise interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017
AT deserresgaston interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017
AT drewsstevenj interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017
AT jassemagatha interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017
AT gubbayjonathanb interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017
AT charesthugues interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017
AT balshawrobert interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017
AT bastiennathalie interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017
AT liyan interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017
AT krajdenmel interimestimatesof201617vaccineeffectivenessagainstinfluenzaah3n2canadajanuary2017

Ejemplares similares